Drug intelligence / Profile preview

BG-111

Development stage: Preclinical
Lead developer: BioGate Precision Medicine
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

BG-111 is a therapeutic cancer protein vaccine being developed by BioGate Precision Medicine, under a technology license from Taipei Veterans General Hospital. It is designed to stimulate the patient's own immune system to produce endogenous antibodies against programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), thereby generating an immune-checkpoint-inhibitor-like effect. BG-111 is currently in the research phase for the treatment of melanoma and other cancers, offering a potentially cost-effective alternative to traditional monoclonal antibody-based checkpoint inhibitors.

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on BG-111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG-111.

Explore the full profile